Release date: 2007-08-02
In a significant development, new coated stents are being introduced to address the critical issue of stent thrombosis. SurModics (Nasdaq: SRDX) and Paragon have entered into a partnership to create an advanced coronary stent system that combines innovative technologies aimed at improving patient outcomes. This collaboration brings together SurModics' FINALE Prohealing coating technology with Paragon's cutting-edge thin-walled stent design, both focused on reducing the risk of stent thrombosis, a rare but severe complication associated with coronary stent procedures.
According to leading interventional cardiologists, while stent thrombosis is uncommon, it can be life-threatening when it occurs. The FINALE coating technology from SurModics is designed to promote natural healing by encouraging the regeneration of endothelial cells and restoring normal vascular function. It not only helps clear newly formed clots but also reduces the likelihood of restenosis, or the re-narrowing of the artery.
By integrating this biologically active coating with Paragon’s ultra-thin stent platform, the new system is expected to offer the benefits of drug-eluting stents without the long-term risks associated with stent thrombosis. Bruce Barclay, CEO of SurModics, expressed confidence in the potential of this technology, citing strong preclinical results. He emphasized the importance of working with partners like Paragon and Apollo to bring innovative solutions to market.
The FINALE coating incorporates extracellular matrix (ECM) proteins, which help enhance the body’s natural healing processes after implantation. These proteins support faster tissue repair and may reduce the risk of future clot formation. Researchers believe that incomplete or delayed endothelial recovery following stent placement could contribute to thrombosis, making the use of ECMs a promising approach.
SurModics has partnered with Dr. Williams, a renowned expert in cardiovascular tissue engineering, to further develop this technology. Their joint efforts include preclinical studies conducted with the University of Arizona, which have shown encouraging results. Meanwhile, Paragon’s stent design uses advanced metallic materials, such as cobalt-based alloys, to create thinner and more flexible stents. These improvements make the devices easier to deliver through catheters and reduce the risk of stent deformation during deployment.
This collaboration represents a major step forward in the field of interventional cardiology, combining advanced materials, biological coatings, and tissue engineering to create a safer and more effective treatment option for patients with coronary artery disease. ——Midi Medical Network
Lake Smelt,Lake Superior Smelt,Pond Smelt,Pond Smelt Fish
ZHEJIANG EVERNEW SEAFOOD CO.,LTD , https://www.evernewseafood.com